On June 2, Reid Hoffman formally notified Microsoft he would not seek re-election to its board in 2026. His notification signals a profound re-alignment of his entrepreneurial focus, shifting him into 'founder mode' for his new AI startup, Manas.
A prominent tech investor is stepping down from a stable, influential board position at a tech giant, but he is doing so to dedicate himself to a high-risk, early-stage AI drug discovery startup. His decision to step down creates a tension between established corporate influence and nascent, disruptive innovation.
Hoffman's move suggests a growing belief among top-tier investors: the next wave of significant value creation lies in applying advanced AI to complex, real-world problems like drug discovery, potentially at the expense of traditional corporate governance roles.
Hoffman's AI Drug Discovery Frontier: Manas
Reid Hoffman is dedicating himself to Manas, an AI drug discovery company that raised over $50 million in seed rounds last year, according to TechCrunch and Livemint. The substantial capital commitment of over $50 million in seed rounds last year underscores significant investor confidence in the nascent AI drug discovery sector, even at an early stage.
Hoffman's decision to leave Microsoft's board after nearly a decade is to enter 'founder mode' with Manas, as reported by Benzinga. While Seattle Times and CNBC suggested an earlier departure, Hoffman formally notified Microsoft on June 2 that he will not stand for re-election at its 2026 annual shareholder meeting, according to GeekWire. His formal notification clarifies his specific exit timeline and full commitment to Manas, highlighting his belief in pioneering complex AI applications for grand challenges.
